Allergic Rhinitis Pipeline To Progress With Novel and Emerging Drugs, Analyzes DelveInsight

New York, USA, May 09, 2022 (GLOBE NEWSWIRE) — Allergic Rhinitis Pipeline To Progress With Novel and Emerging Drugs, Analyzes DelveInsight

Allergic Rhinitis Pipeline involves 32+ key companies continuously working towards developing 32+ Allergic Rhinitis treatment therapies, as per DelveInsight.

DelveInsight’s ‘Allergic Rhinitis Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Allergic Rhinitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Allergic Rhinitis pipeline domain.

Key Takeaways from the Allergic Rhinitis Pipeline Report

• DelveInsight’s Allergic Rhinitis Pipeline analysis depicts a robust space with 32+ active players working to develop 32+ pipeline therapies for Allergic Rhinitis treatment. 
• The leading Allergic Rhinitis companies include Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals Inc., Revolo Biotherapeutics, Emergo Therapeutics, Advagene Biopharma, AOBiome LLC, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Siolta Therapeutics, Worg Pharmaceuticals, ABVC Biopharma, Revelation Biosciences,  Altamira Therapeutics, Qyuns Therapeutics, Dobecure, Funpep, GL Pharm Tech, Archivel Farma, Nasus Pharma, RIKEN, Paradigm Pharmaceuticals,  DC4U, United Biomedical, Marinomed Biotech, Desentum,  Roxall Medizin and others are evaluating their lead assets to improve the Allergic Rhinitis treatment landscape.
• Key Allergic Rhinitis pipeline therapies in various stages of development include AI-201901, Injectable MPL allergy vaccine, REGN5713-5714-5715, House dust mite allergy immunotherapy, Birch pollen allergy vaccine tablet, B 244, AD 17002, CSPCHA-115, MM09-MG01, MG 01/T 517, IRL 201104, REVTx-99b, QX 005N, FPP004, GLF1MO, INI2004, RUTI, FMXIN002,   UB-211and others.
• In January 2022, Glenmark announced the approval of Ryaltris. Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients 12 years of age and older. Glenmark in January 2022 entered into licensing agreement with Lotus International wholly owned subsidiary of Lotus Pharmaceutical, for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong, and Vietnam. 
• In January 2022, Revelation Biosciences dosed and enrolled the first patient in a Phase Ib clinical study to evaluate the potential utility of REVTx-99 in treating patients with allergic rhinitis and patients with chronic nasal congestion without polyps. The clinical study is being conducted in Australia.
• Paradigm Pharmaceuticals focus remains on exploring Pentosan Polysulfate Sodium (PPS) use in treating the myriad conditions that begin with and are sustained by inflammation. The company is evaluating the use of PPS in chronic heart failure (CHF), treating alphavirus induced arthralgia (in patients with Ross River Virus and Chikungunya); and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).
• In May 2022, ABVC Biopharma announced that BioKey, a wholly-owned subsidiary of the company based in Fremont, California, entered into a $3.0 million clinical services contract with NeuCen BioMed Co. Ltd. to guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under US FDA IND regulatory requirements. CEN501 is a nasal strip product used as a local nasal immunotherapy (LNIT) for the treatment of mite-induced allergic rhinitis patients.
• In March 2022, Altamira Therapeutics announced completion of patient enrollment in its Bentrio trial in house dust mite (“HDM”) allergic rhinitis. The Company expects to release top-line results from the trial during the second quarter of 2022.

Request a sample and discover the recent breakthroughs happening in the Allergic Rhinitis pipeline landscape @ Allergic Rhinitis Pipeline Outlook

The Allergic Rhinitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Allergic Rhinitis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Allergic Rhinitis pipeline landscape.

Allergic Rhinitis Overview

Allergic rhinitis is a condition that happens when the body’s immune system overreacts to anything in the environment (triggers). It is caused by allergens, which are normally harmless compounds that provoke an allergic reaction in some people. Some individuals name it hay fever when the Allergic Rhinitis symptoms appear in late summer or early fall.  The common Allergic Rhinitis causes include dust mites, mold, pet dander, and pollen from trees and plants. The symptoms of Allergic Rhinitis include sneezing, nasal congestion, and irritation of the nose, throat, mouth, and eyes.

A complete history is used to make an Allergic Rhinitis diagnosis, which is then confirmed by examination findings (physical examination and, if necessary, nasal endoscopy) and, if necessary, allergen-specific IgE testing. Other tests for Allergic Rhinitis diagnosis such as a nasal allergen challenge, CT scans, evaluation of nasal nitric oxide and ciliary beat frequency, nasal smears, nasal cultures, and -transferrin analysis of nasal fluid may be necessary to include or exclude distinct types of rhinitis.

The major Allergic Rhinitis treatment options include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays, leukotriene receptor antagonists (LTRAs), and allergen immunotherapy.

Find out more about Allergic Rhinitis medication @ Best Antihistamine for Allergic Rhinitis 

A snapshot of the Allergic Rhinitis Pipeline Drugs mentioned in the report:

Learn more about the novel and emerging Allergic Rhinitis pipeline therapies @ Allergic Rhinitis Clinical Trials

Allergic Rhinitis Therapeutics Assessment

The Allergic Rhinitis Pipeline report proffers an integral view of the Allergic Rhinitis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the Allergic Rhinitis Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravitreal
• Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
• Therapeutics Assessment By Mechanism of Action: Immunomodulators, IgE receptor modulators, 
• Key Allergic Rhinitis Companies: Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, Revelation Biosciences and others.
• Key Allergic Rhinitis Pipeline Therapies: AI-201901, Injectable MPL allergy vaccine, REGN5713-5714-5715, House dust mite allergy immunotherapy, Birch pollen allergy vaccine tablet, B 244, AD 17002, CSPCHA-115, MM09-MG01, MG 01/T 517, REVTx-99b and others.

Dive deep into rich insights for drugs used for Allergic Rhinitis treatment, visit @ Allergic Rhinitis Drugs 

Table of Contents

For further information on the Allergic Rhinitis therapy in the pipeline, reach out @ Allergic Rhinitis Medication

Related Reports

Allergic Rhinitis Epidemiology Forecast

Allergic Rhinitis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Allergic Rhinitis epidemiology in the 7MM.

Allergic Rhinitis Market

Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Allergic Rhinitis companies such as Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., among others.

Perennial Allergic Rhinitis Pipeline

Perennial Allergic Rhinitis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Perennial Allergic Rhinitis companies such as ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, among others.

Seasonal Allergic Rhinitis Pipeline

Seasonal Allergic Rhinitis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Seasonal Allergic Rhinitis companies such as Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, among others.

Perennial Allergic Rhinitis Market

Perennial Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Perennial Allergic Rhinitis companies such as ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, among others.

Seasonal Allergic Rhinitis Market

Seasonal Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Seasonal Allergic Rhinitis companies such as Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, among others.

Other Trending Reports

Hemostasis Market

Hemostasis Market Research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hemostasis market size, share, and trends in the 7MM.

Delirium Market

“Delirium Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Delirium market size, share, and trends in the 7MM.

Liver Angiosarcoma Market

“Liver Angiosarcoma Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Liver Angiosarcoma market size, share, and trends in the 7MM.

Endometrial Hyperplasia Market

“Endometrial Hyperplasia Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Endometrial Hyperplasia market size, share, and trends in the 7MM.

Maple Syrup Urine Disease Market

“Maple Syrup Urine Disease Market” research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Maple Syrup Urine Disease market size, share, and trends in the 7MM.

Related Healthcare Blogs

Allergic Rhinitis Market

Most Common Food Allergies

Allergic Disease Market Landscape

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter